Business Segments · Operating Income (Loss)
Biotechnology — Operating Income (Loss)
Danaher Biotechnology — Operating Income (Loss) decreased by 1.1% to $534M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21.1%, from $441M to $534M. Over 2 years (FY 2023 to FY 2025), Biotechnology — Operating Income (Loss) shows relatively stable performance with a -1.2% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2022
Last reportedQ1 2026Apr 21, 2026
Rolls up toOperating Income
How to read this metric
An increase indicates improved operational efficiency or stronger pricing power.
Detailed definition
The profit or loss generated by the biotechnology segment after deducting operating expenses from total revenue. This is...
Peer comparison
Standard segment-level profitability metric across all industries.
Metric ID:
dhr_segment_biotechnology_operating_income_lossHistorical Data
16 periods
| Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $800M | $824M | $691M | $596M | $480M | $417M | $416M | $325M | $462M | $390M | $508M | $441M | $531M | $352M | $540M | $534M |
| QoQ Change | — | +3.0% | -16.1% | -13.7% | -19.5% | -13.1% | -0.2% | -21.9% | +42.2% | -15.6% | +30.3% | -13.2% | +20.4% | -33.7% | +53.4% | -1.1% |
| YoY Change | — | — | — | -25.5% | -41.7% | -39.7% | — | -45.5% | -3.8% | -6.5% | +22.1% | +35.7% | +14.9% | -9.7% | +6.3% | +21.1% |
Range$325M – $824M
CAGR-10.2%
Avg YoY Growth-6.0%
Median YoY Growth-5.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Danaher's biotechnology — operating income (loss)?
- Danaher (DHR) reported biotechnology — operating income (loss) of $534M in Q1 2026.
- How has Danaher's biotechnology — operating income (loss) changed year-over-year?
- Danaher's biotechnology — operating income (loss) increased by 21.1% year-over-year, from $441M to $534M.
- What is the long-term trend for Danaher's biotechnology — operating income (loss)?
- Over 2 years (2023 to 2025), Danaher's biotechnology — operating income (loss) has grown at a -1.2% compound annual growth rate (CAGR), from $1.91B to $1.86B.
- What does biotechnology — operating income (loss) mean?
- The core profit or loss generated by the biotechnology business segment.